Belmont Global Advisors buys $1,092,600 stake in La Jolla Pharmaceutical Company (LJPC)

La Jolla Pharmaceutical Company (LJPC) : Belmont Global Advisors scooped up 10,000 additional shares in La Jolla Pharmaceutical Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 60,000 shares of La Jolla Pharmaceutical Company which is valued at $1,092,600.La Jolla Pharmaceutical Company makes up approximately 1.98% of Belmont Global Advisors’s portfolio.

Other Hedge Funds, Including , Walleye Trading sold out all of its stake in LJPC during the most recent quarter. The investment firm sold 100 shares of LJPC which is valued $1,821.Teachers Advisors Inc boosted its stake in LJPC in the latest quarter, The investment management firm added 56 additional shares and now holds a total of 23,042 shares of La Jolla Pharmaceutical Company which is valued at $419,595. Credit Suisse Ag added LJPC to its portfolio by purchasing 32,741 company shares during the most recent quarter which is valued at $596,214.Diam Ltd. boosted its stake in LJPC in the latest quarter, The investment management firm added 9,379 additional shares and now holds a total of 142,696 shares of La Jolla Pharmaceutical Company which is valued at $2,649,865. La Jolla Pharmaceutical Company makes up approx 0.04% of Diam Ltd.’s portfolio.

La Jolla Pharmaceutical Company opened for trading at $16.33 and hit $16.56 on the upside on Thursday, eventually ending the session at $16.48, with a gain of 0.80% or 0.13 points. The heightened volatility saw the trading volume jump to 40,768 shares. Company has a market cap of $301 M.

Many Wall Street Analysts have commented on La Jolla Pharmaceutical Company. SunTrust Initiated La Jolla Pharmaceutical Company on Jun 22, 2016 to “Buy”, Price Target of the shares are set at $30.Lake Street Initiated La Jolla Pharmaceutical Company on May 24, 2016 to “Buy”, Price Target of the shares are set at $25.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. Its four product candidates in development include LJPC-501 GCS-100 LJPC-1010 and LJPC-401. LJPC-501 is its formulation of angiotensin for the treatment of catecholamine-resistant hypotension (CRH). GCS-100 is its galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010 is its galectin-3 inhibitor. LJPC-401 is its formulation of hepcidin for the potential treatment of conditions characterized by iron overload such as hemochromatosis and beta thalassemia.

Leave a Reply

La Jolla Pharmaceutical Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on La Jolla Pharmaceutical Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.